Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Christine S. Ferrer"'
Autor:
Walid Faraj, Mark Robson, Ayman Tawil, Victor Reuter, Rami Mahfouz, Roy Cambria, Nour Saheb, Christine S. Ferrer, Shreya Vemuri, Marita Yaghi, Mariam Kanso, Abdul Abdullah, Ghina El Nounou, Mark Jabbour, Kerri Muenkel, Kristopher Kaufman, Joe-Max Wakim, Sandy Badson, Roger Wilson, Collette Houston, Marija Drobnjak, Jamal Hoballah, Fuad N. Ziyadeh, Ghazi Zaatari, Murray Brennan, Eileen M. O'Reilly, Ali K. Abu-Alfa, Ghassan K. Abou-Alfa
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
PURPOSEBiobanking helps source tissue and blood for studying cancer genomics. Access to biorepository resources in low- and middle-income countries is lacking. Memorial Sloan Kettering Cancer Center (MSK) and the American University of Beirut (AUB) e
Externí odkaz:
https://doaj.org/article/ba15bd7bb976447c8ae7bb37e2d578be
Autor:
Ghassan K. Abou-Alfa, Peter Kuhn, Jinru Shia, James J. Harding, Christine S. Ferrer, Danny N. Khalil, Joanne F. Chou, Benjamin R. Tan, Marinela Capanu, Hooman Yarmohammadi, Mariam Rodriguez-Lee, Chayma Boussayoud, Kerri E. Muenkel, Renuka Iyer, Carmen Ruiz, Gian Kinh Do, Imane El Dika, Robin Kate Kelley, John Wilton
Publikováno v:
Oncologist
The oncologist, vol 25, iss 12
The oncologist, vol 25, iss 12
Lessons Learned Androgen receptor as assessed by immunohistochemistry is expressed in a high proportion of patients with hepatocellular carcinoma (HCC). Enzalutamide at 160 mg orally daily is safe and tolerable in patients with advanced HCC but has n
Autor:
Neha Korde, Heather Landau, Obadi Obadi, Ruthee Bayer, Allison Parascondola, Malin Hultcrantz, Jennifer Acosta, Oscar B Lahoud, David J. Chung, Sham Mailankody, Saurabh Chhabra, Leeann Marcello, Christine S. Ferrer, Alexander M. Lesokhin, Sergio Giralt, Luciano J. Costa, Hani Hassoun, Gunjan L. Shah, Cesar Rodriguez, Susan Bal, Carlyn Tan, Jonathan Lambird, Leah Shulman, Urvi A Shah, Michael Scordo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S158-S159
Background Despite major advances in multiple myeloma (MM) therapy, most patients relapse after primary treatment. We present the interim analysis of a phase II multicenter trial evaluating the efficacy of daratumumab, carfilzomib (27 mg/m2 twice wee
Autor:
James J. Harding, Hooman Yarmohammadi, Kim Anna Reiss, Joanne F. Chou, Marinela Capanu, Richard K. G. Do, Danny Khalil, Imane H. El Dika, Christine S. Ferrer, Olivia Heffernan, J Daniel Giardina, Taha Merghoub, William R. Jarnagin, Gregory Nadolski, Joseph Patrick Erinjeri, Michael C. Soulen, Benjamin R. Tan, Ghassan K. Abou-Alfa
Publikováno v:
Journal of Clinical Oncology. 40:437-437
437 Background: TACE is a standard of care for liver limited HCC and impacts the immune microenvironment, potentially augmenting the effects of immune checkpoint inhibitors. Methods: This is a multicenter phase 1 study of NIVO and deb-TACE in unresec